Director MaryAnn Wright filed a Form 4 with the SEC on November 3, 2026, disclosing the acquisition of 610 deferred shares of Brunswick Corporation common stock on October 30, 2026.
Director J. Steven Whisler filed a Form 4 with the SEC on November 3, 2026, disclosing the acquisition of 1,076 deferred shares of Brunswick Corporation common stock on October 30, 2026.
Director David C. Everitt filed a Form 4 with the SEC on November 3, 2026, disclosing the acquisition of 776 deferred shares of Brunswick Corporation common stock on October 30, 2026.
Director Roger Wood filed a Form 4 with the SEC on November 3, 2026, disclosing the acquisition of 614 shares of Brunswick Corporation common stock on October 30, 2026.
Director and 10% owner Steven I. Sarowitz filed a Form 4 with the SEC on November 3, 2026, reporting the sale of 6,374 shares of Paylocity Holding Corp common stock on October 30, 2026, under a Rule 10b5-1 plan.
Director Joseph W. McClanathan filed a Form 4 with the SEC on November 3, 2026, disclosing the acquisition of 589 shares of Brunswick Corporation common stock on October 30, 2026.
Director Lauren Patricia Flaherty filed a Form 4 with the SEC on November 3, 2026, disclosing the acquisition of 589 deferred shares of Brunswick Corporation common stock on October 30, 2026.
Marion McCourt, Executive Vice President Commercial at Regeneron Pharmaceuticals, Inc., filed a Form 4 on November 3, 2026, disclosing the sale of 1,132 shares of common stock on October 30, 2026, under a Rule 10b5-1 trading plan.
Stephane de la Faverie, President and CEO of Estee Lauder Companies Inc., filed a Form 4 on November 3, 2026, disclosing RSU vesting transactions in Class A Common Stock dated November 2, 2026.
Director and 10% owner William P. Lauder filed a Form 4 with the SEC on November 3, 2026, reporting the vesting and partial tax-related disposition of restricted stock units in Estee Lauder Companies Inc. on November 2, 2026.